Cited by 433SARS-CoV-2 and COVID-19 Researchinterferon and immune responsesAnimal Virus Infections Studies

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Open access
Konno, Yoriyuki, Kimura, Izumi, Uriu, Keiya, Fukushi, Masaya, Irie, Takashi, Koyanagi, Yoshio, Sauter, Daniel, Gifford, Robert J. +2 more·2020·Cell Reports

Published version of a preprint

Abstract

Abstract One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays revealed that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of more than 15,000 SARS-CoV-2 sequences identified a natural variant, in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients, but also describe a possibility of the emergence of natural SARS-CoV-2 quasispecies with extended ORF3b that may exacerbate COVID-19 symptoms. Highlights ORF3b of SARS-CoV-2 and related bat and pangolin viruses is a potent IFN antagonist SARS-CoV-2 ORF3b suppresses IFN induction more efficiently than SARS-CoV ortholog The anti-IFN activity of ORF3b depends on the length of its C-terminus An ORF3b with increased IFN antagonism was isolated from two severe COVID-19 cases

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2020.108185

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A main evasion strategy seems to be blocking type I interferon responses at several steps, such as viral RNA recognition, nuclear translocation of inflammatory transcription factors, and STAT1/STAT2 phosphorylation.

    “A predominant strategy appears to be the inhibition of the type I interferon response58–60 at multiple points, including impaired recognition of viral RNA61,62, decreased nuclear translocation of pro-inflammatory transcription factors (such as IRF3, IRF7 and STAT1)61,63 and suppression of STAT1 and STAT2 phosphorylation64,65.”
  • Functional testing supported the counteracting activity of ORF3b, ORF6, NSP1, or NSP13 on type I IFN activation, with ORF6 particularly suppressing STAT1 and STAT2 phosphorylation and STAT1 nuclear translocation.

    “Functional testing further supported the counteracting activity of ORF3b, ORF6, NSP1, or NSP13 on type I IFN activation, of which particularly ORF6 suppressed STAT1 and STAT2 phosphorylation and STAT1 nuclear translocation, (Konno et al., 2020; Lei et al., 2020; Xia et al., 2020).”

    From COVID-19 and the human innate immune system (2021) · cites this paper as Konno et al., 2020

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R. J., Nakagawa, S., & Sato, K.
Affiliations
  • Institute of Medical Science, The University of Tokyo (JP)
  • Hiroshima University (JP)
  • Kyoto University (JP)
  • Universität Ulm (DE)
  • MRC University of Glasgow Centre for Virus Research (GB)
  • Tokai University (JP)
Corresponding author
Sato, Kei
Venue
Cell Reports
Publisher
Elsevier BV
Published
2020-09
Volume
32
Issue
12
Pages
108185
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3082709602
Cited by
433
References
48
Citations by year
2026: 7 · 2025: 23 · 2024: 35 · 2023: 48 · 2022: 101 · 2021: 155 · 2020: 64
FWCI
12.10
Type
journal article
Language
en
Open access
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Takeda Science Foundation
  • Daiichi Sankyo Foundation of Life Science
  • Bundesministerium für Bildung und Forschung
  • Japan Agency for Medical Research and Development (20fk0410014, 20fk0108146, 19fk0108171, 20fk0108270, 19fk0410019)
  • Uehara Memorial Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Institute of Medical Science, University of Tokyo
  • Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
  • Canon Foundation in Europe
  • Lotte Foundation
  • Institute for Frontier Life and Medical Sciences, Kyoto University
  • Ono Medical Research Foundation
  • University of Tokyo (2020-K3003)
  • Japan Society for the Promotion of Science (17H05823, 19H04843, 19H04837, 17H05813, 19H04826, 18H02662, 16K21723, 16H06429, DC1 19J22914, DC1 19J20488)
  • Hiroshima University
  • Sumitomo Foundation
  • Japan Science and Technology Agency (JPMJJR2007)
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, interferon antagonism, type I interferon induction, premature stop codon, SARS-CoV, bat coronaviruses, pangolin coronavirus, quasispecies, COVID-19 pathogenesis, severe COVID-19
MeSH terms
Eutheria, Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Amino Acid Sequence, Animals, Chiroptera, Humans, Interferon Type I, Male, Pneumonia, Viral, Coronavirus Infections, Codon, Nonsense, Viral Regulatory and Accessory Proteins, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review